research

Breath Test May Detect Signs of Lung Cancer: Study

Examining breath samples from patients with suspicious growths might help determine who needs surgery

Researchers tested the exhaled breath of people with suspicious lung lesions that were detected on CT scans. The breath was tested for levels of four cancer-specific substances, called “carbonyls.”

The breath samples were analyzed using a special device developed at the University of Louisville.

Having elevated levels of three of the four carbonyls was predictive of lung cancer in 95 percent of patients, while having normal levels of these substances was predictive of a noncancerous growth in 80 percent of patients, the researchers found.
Elevated carbonyl levels returned to normal after lung cancer patients had surgery to remove the cancer, according to the study, which was to be presented Tuesday at the Society of Thoracic Surgeons annual meeting in Orlando, Fla.

“Instead of sending patients for invasive biopsy procedures when a suspicious lung mass is identified, our study suggests that exhaled breath could identify which patients” may be referred for immediate surgery, study author Dr. Michael Bousamra, of the University of Louisville, said in a society news release.

This approach offers something new, he said, including “the simplicity of sample collection and ease for the patient.”

The data and conclusions of research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

Source: webmd

Low-sugar vs. low-fat: Twin doctors experiment to see which diet works best

In the quest to lose weight, is cutting out sugar or cutting out fat the solution?

To find the answer, 35-year-old identical twins Chris and Xand van Tulleken, who are both doctors, conducted a month-long experiment. While Chris, a physician at University College Hospital, London went on a low-fat, high-carb regime, Xand, director of the Institute of Humanitarian Affairs at Fordham University in New York, chose a high-fat, low-carb diet.

The brothers both lost weight. Xand lost the most– nine pounds in one month.

In conclusion, the brothers found that eliminating a single macro-nutrient like fat or sugar is not a solution to weight loss, nor are fad diets.

“It is about building an environment in your life where you could easily eat a cheap and healthy diet and get enough exercise. It is amazing that we are not all fat and I come away with a sense that I know enough about diet and nutrition and I should be reducing the calories and building an environment where I can do that rather than looking for one toxic ingredient,” Chris said.

After the experiment ended, the British twins also concluded that the real villains when it comes to weight gain are processed foods that contained a combination of high fat and high sugar.

Susan Jebb, professor of diet and population health at the University of Oxford, agreed with their conclusion.

“Processed foods pack calories in and are unbelievably attractive and delicious,” she told the Daily Express. “They are temptations for all of us and it is astonishing that any of us stay slim.”

The brothers’ experiment will be featured in the UK on BBC Two’s Horizon program tonight.

Source: met4love

Large amounts of folic acid could lead to development of breast cancer

A scientist shown for the first time that folic acid supplements in doses 2.5 to five times the daily requirement “significantly promotes” the growth of existing pre-cancerous or cancerous cells in the mammary glands of rats.

Dr. Young-In Kim said that this is a critically important issue because breast cancer patients and survivors in North America are exposed to high levels of folic acid through folic acid fortification in food and widespread use of vitamin supplements after a cancer diagnosis.

The amount of folic acid consumed in North America has increased dramatically in the past 15 years. Women are routinely advised to take folic acid supplements before becoming pregnant and while pregnant to prevent neural tube birth defects such as spina bifida.

His research was published in the online journal PLOS ONE.

Source: healcon

Artificial Bone Marrow Could Be Used to Treat Leukemia

download

Artificial bone marrow may be used to reproduce hematopoietic stem cells. A prototype has now been developed by scientists of KIT, the Max Planck Institute for Intelligent Systems, Stuttgart, and Tübingen University. The porous structure possesses essential properties of natural bone marrow and can be used for the reproduction of stem cells at the laboratory. This might facilitate the treatment of leukemia in a few years.

The researchers are now presenting their work in the journal Biomaterials.
Blood cells, such as erythrocytes or immune cells, are continuously replaced by new ones supplied by hematopoietic stem cells located in a specialized niche of the bone marrow. Hematopoietic stem cells can be used for the treatment of blood diseases, such as leukemia. The affected cells of the patient are replaced by healthy hematopoietic stem cells of an eligible donor.

However, not every leukemia patient can be treated in this way, as the number of appropriate transplants is not sufficient. This problem might be solved by the reproduction of hematopoietic stem cells. So far, this has been impossible, as these cells retain their stem cell properties in their natural environment only, i.e. in their niche of the bone marrow. Outside of this niche, the properties are modified. Stem cell reproduction therefore requires an environment similar to the stem cell niche in the bone marrow.

The stem cell niche is a complex microscopic environment having specific properties. The relevant areas in the bone are highly porous and similar to a sponge. This three-dimensional environment does not only accommodate bone cells and hematopoietic stem cells but also various other cell types with which signal substances are exchanged. Moreover, the space among the cells has a matrix that ensures a certain stability and provides the cells with points to anchor. In the stem cell niche, the cells are also supplied with nutrients and oxygen.

The Young Investigators Group “Stem Cell-Material Interactions” headed by Dr. Cornelia Lee-Thedieck consists of scientists of the KIT Institute of Functional Interfaces (IFG), the Max Planck Institute for Intelligent Systems, Stuttgart, and Tübingen University. It artificially reproduced major properties of natural bone marrow at the laboratory. With the help of synthetic polymers, the scientists created a porous structure simulating the sponge-like structure of the bone in the area of the blood-forming bone marrow. In addition, they added protein building blocks similar to those existing in the matrix of the bone marrow for the cells to anchor.

The scientists also inserted other cell types from the stem cell niche into the structure in order to ensure substance exchange.
Then, the researchers introduced hematopoietic stem cells isolated from cord blood into this artificial bone marrow. Subsequent breeding of the cells took several days. Analyses with various methods revealed that the cells really reproduce in the newly developed artificial bone marrow. Compared to standard cell cultivation methods, more stem cells retain their specific properties in the artificial bone marrow.

The newly developed artificial bone marrow that possesses major properties of natural bone marrow can now be used by the scientists to study the interactions between materials and stem cells in detail at the laboratory. This will help to find out how the behavior of stem cells can be influenced and controlled by synthetic materials. This knowledge might contribute to producing an artificial stem cell niche for the specific reproduction of stem cells and the treatment of leukemia in ten to fifteen years from now.

Source: Science daily

Genome of the Blood-Sucking Hookworm Decoded

Scientists have decoded the genome of a lowly, blood-sucking hookworm, an advance they say could lead to cures for hookworm infection, a painful condition afflicting more than 700 million people worldwide, mostly in underdeveloped countries.

But the worm’s unique relationship with the human immune system means the new findings may also provide insights into treating autoimmune diseases rampant in the United States, such as inflammatory bowel disease, multiple sclerosis, asthma and allergies.

An international team of scientists focused on one of the two main hookworm species that affects humans, Necator americanus. These parasites start their lives in soil, and enter the human body through the foot, where they embark on a fantastic voyage through the blood vessels, to the heart, then into the lungs and trachea before being coughed up and swallowed and carried to their final home in the small intestine.

Once in the intestines, the centimeter-long worms can live for up to five years, mating and producing 10,000 eggs daily. They feed on blood, so much so that an infected person can become iron deficient through blood loss. For children, infection can stunt growth and cause severe cognitive deficits.

The decoded genome of Necator americanus, published today (Jan. 19) in the journal Nature Genetics, may reveal an Achilles heel — a pathway for a vaccine or drug that could either kill the worms, thwart their reproduction, or minimize the damage of their infestation.

“We now have a more complete picture of just how this worm invades the body, begins feeding on the blood, and successfully evades the host immune defenses,” said Dr. Makedonka Mitreva of Washington University School of Medicine in St. Louis, senior author on the report, which included researchers in Australia, Singapore and Brazil.

Hookworm disease is endemic through much of the warm, rural world where people lack indoor plumbing, and is particularly common in poorer regions where children have no shoes to protect their feet. Hookworm disease was once prevalent in the southern United States, and was a major public health concern there as recently as the 1940s.

Hookworm infection is not deadly for most people, although newborns and pregnant women may die from infection. However, its reoccurring nature takes its toll in the form of chronic anemia and lassitude, leading to slow learning among children, low productivity among affected working adults, and a continuation of the cycle of poverty.

Deworming drugs are available, and are often relatively inexpensive, but their repeated and excessive use is leading to drug resistance in some regions.

Improved sanitation and use of shoes are proven to reduce infections, as was shown in the American rural south. Yet in desperately poor regions of the world, new drugs or a one-time vaccine would be a godsend.

Such treatments could arise from research on the decoded hookworm genome, Mitreva said.

The study of the hookworm could lead to treatments of other diseases as well.

One of the silver linings of chronic worm infection is that the vigorous workout it gives the immune system of an infected person is associated with a reduced risk of allergies and autoimmune conditions. Indeed, helminthic therapy —deliberately infecting a person with helminths, a group of parasites that include hookworms, tapeworms, and roundworms — recently has shown progress in the treatment of Crohn’s disease, a type of inflammatory bowel disease, as well as other immune-mediated diseases.

As part of decoding of the Necator americanus genome, the researchers identified a group of molecules that appears to protect the worm from detection by the host immune system. Hookworms evade notice by suppressing molecules that promote inflammation. This very same approach, the researchers wrote, may prove valuable in the treatment of autoimmune conditions.

“It is our hope that the new research can be used as a springboard, not just to control hookworm infections, but to identify anti-inflammatory molecules that have the potential to advance new therapies for autoimmune and allergic diseases,” Mitreva said.

Necator americanus and its hookworm cousin, Ancylostoma duodenale, also can infect dogs and cats. And under certain conditions, your pet’s hookworms could infect you, for example, if the pet feces in your backyard contain the worm’s eggs, and soil conditions are right.

Source: Yahoo news

Stem cell breakthrough explains how breast cancer spreads

Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, a new study has revealed.

Study’s senior author Max S. Wicha from University of Michigan Comprehensive Cancer Center said the lethal part of cancer is its metastasis so understanding how metastasis occurs is critical.

“We have evidence that cancer stem cells are responsible for metastasis – they are the seeds that mediate cancer’s spread. Now we’ve discovered how the stem cells do this,” Wicha said.

First, on the outside of the tumor, a type of stem cell exists in a state called the epithelial-mesenchymal transition (EMT) state. These stem cells appear dormant but are very invasive and able to get into the bloodstream, where they travel to distant parts of the body.

Once there, the stem cells transition to a second state that displays the opposite characteristics, called the mesenchymal-epithelial transition state (MET). These cells are capable of growing and making copies of themselves, producing new tumors.

The study looked specifically at breast cancer stem cells but the researchers believe the findings likely have implications for other cancer types as well.

The study was published in the journal of Stem Cell Reports.

Source: ANI

 

Gene therapy reverses blinding eye disease

An experimental therapy for a blinding eye disease showed early – and surprising – promise when it improved the vision of patients in an early trial that was only supposed to test its safety, doctors reported Wednesday.

The experimental gene therapy not only stopped the steady degeneration of the patients’ vision, but appears to have reversed some of the damage. And the effects have lasted two years in one case, British researchers report in the Lancet medical journal.

Wayne Thompson of Staffordshire in Britain saw the stars for the first time in years after being treated in April.

“One night in the summer, my wife called me outside as it was a particularly starry evening. As I looked up, I was amazed that I was able to see a few stars,” Thompson, 43, said in a statement.

“I hadn’t seen stars for a long, long time,” he added.

“It is still too early to know if the gene therapy treatment will last indefinitely, but we can say that the vision improvements have been maintained for as long as we have been following up the patients, which is two years in one case,” says Dr. Robert MacLaren of the Nuffield Laboratory of Ophthalmology at the University of Oxford, who leads the research team.

“In truth, we did not expect to see such dramatic improvements in visual acuity and so we contacted both patients’ home opticians to get current and historical data on their vision in former years, long before the gene therapy trial started. These readings confirmed exactly what we had seen,” he added in a statement.

The men taking part in the trial all have choroideremia, a genetic disease that causes vision to start breaking down when patients are still children. The defective gene, called CHM, is on the x chromosome, so it almost exclusively affects males – females have an extra x chromosome that usually makes up for any lost function. It causes about 4 percent of all cases of blindness, according to the National Institutes of Health.

The condition breaks down various parts of the retina, the reflective tissue at the back of the eye that collects light and images. The gene therapy approach uses a virus to carry a corrective gene directly into the retina.

Gene therapy itself has a mixed record – it’s harder than scientists thought to safely deliver new genes into the body. And there is no guarantee that the patient’s cells will accept the new gene and use it.

But the eye is a good place to try, in part because doctors can see the effects in real time, and also because one eye can be treated and the other eye used to compare results.

“I think that this is a very important study,” said Dr. Richard Weleber, professor of ophthalmology who is leading a team at Oregon Health and Science University trying gene therapy to treat Usher Syndrome.

MacLaren’s trial was meant to be a stage 1 safety trial, designed simply to show that the treatment did no harm. But the six patients in the trial said they noticed improvements quickly.

“This has huge implications for anyone with a genetic retinal disease such as age-related macular degeneration or retinitis pigmentosa, because it has for the first time shown that gene therapy can be applied safely before the onset of vision loss,” MacLaren said.

He says nine patients have now had one eye treated with the gene therapy in operations at the Oxford Eye Hospital. The patients had varying degrees of vision loss, but MacLaren thinks the best course will be to treat people when they are young, before much damage has been done.

“If we were able to treat people early, get them in their teens or late childhood, we’d be getting the virus in before their vision is lost,” he said. “If the treatment works, we would be able to prevent them from going blind.”

Weleber, who says his own gene therapy trial is moving along but who could not release details, says MaCLaren’s surgical technique may have helped the therapy work more successfully. MacLaren’s team lifted an area called the macula to deliver the engineered viruses directly into the tissue that needed correcting.

Last year, researchers reported success against a different genetic disease causing blindness , one called Leber congenital amaurosis. But even though the patients’ vision improved, the eye continued to deteriorate.

“Each type (of genetic disease) needs to be tested separately,” Weleber said.

Gene therapy also works to some degree against blood cancers and immune diseases.

Last year, doctors reported they had successfully treated the first children in the U.S. for severe combined immune deficiency or SCID, sometimes known as “bubble boy” disease. Like choroideremia, SCID is caused by a mutated recessive gene, meaning children must inherit a defective copy from each parent to show symptoms.

Gene therapy has helped 26 of 59 two patients with a form of cancer called chronic lymphocytic leukemia go into remission after a type of gene therapy treatment that programmed immune system cells to hunt down and kill the leukemia cells. And last year doctors reported 24 people with acute lymphocytic leukemia got at least temporary remission after gene therapy.

Source: nbc news

Scientists discover new way of overcoming human stem cell rejection

Human embryonic stem cells have the capacity to differentiate into a variety of cell types, making them a valuable source of transplantable tissue for the treatment of numerous diseases, such as Parkinson’s disease and diabetes.

But there’s one major issue: Embryonic stem cells are often rejected by the human immune system.

Now, researchers from the University of California San Diego may have found an effective way to prevent this rejection in humans. Utilizing a novel humanized mouse model, the scientists have revealed a unique combination of immune suppressing molecules that stop the immune system from attacking the injected stem cells – without shutting the system down completely.

This discovery could ultimately help resolve some of the major problems currently limiting the use of embryonic stem cells for certain conditions, paving the way for the development of more effective human stem cell therapies.

“This is a generic way of immune suppression, so it could potentially be applied not just for stem cells therapies, but for organ transplants as well,” Yang Xu, a professor of biology at UC San Diego and lead author of the study, told FoxNews.com. “It can be very broad.”

Embryonic stem cells are different from the other cells in a patient’s body, making them “allogenic.” This means the immune system will recognize them as foreign agents and attack them.

One way of overcoming this rejection problem is to give patients immunosuppressant drugs, which suppress the entire immune system. While short term use of immunosuppressants has been successful for many organ transplants, embryonic stem cell therapies for chronic diseases require long term use of these drugs – which can often be very toxic and increase the risk of cancer.

“In order for the patient to really use this therapy, they have to decide: Do they want a lifelong use of immunosuppressant drugs, or are they willing to live with the symptoms of their disease,” Xu said.

Source: news.nom

New genetic marker to predict bird flu severity

Australian scientists Tuesday said they have discovered a genetic marker that can accurately predict the severity of the H7N9 avian influenza.

Researchers at the University of Melbourne claimed that by using genetic markers to blood and lung samples, they discovered certain indicators that signal increased susceptibility to this avian influenza, a statement said.

Katherine Kedzierska, associate professor at the department of microbiology and immunology at the university, said that being able to predict which patient will be more susceptible to the emerging avian influenza strain will allow experts to better manage the disease.

“Higher than normal levels of cytokines (a type of protein), driven by a genetic variant of a protein called IFITM3, tells us that the severe disease is likely,” Kedzierska said.

“We call this a Cytokine Storm and people with the defective genetic variant of the protein IFITM3 are more likely to succumb to severe influenza infection,” she added.

Peter Doherty, a lead author of the study, said predicting how avian influenza works in individuals has implications for the management of disease and the resources on our health system.

Source: Business Standard

India launches its indigenous cervical cancer screening device

India launched its first indigenously developed device for screening and early detection of cervical cancer, which kills over 74,000 women in the country every year.

Launching the low-cost “AV-Magnivisualiser” device developed by Indian Council of Medical Research (ICMR), Union Minister of Health and Family Welfare Ghulam Nabi Azad said it will help in early detection of cervical cancer among adolescent girls and women, thus helping in save many lives.

Designed and developed at Institute of Cytology and Preventive Oncology ( ICPO), Noida, working under ICMR, the device will cost about Rs 10,000 and is much lower as compared to the cervical cytology method used at present in medical colleges, the equipment of which costs over Rs eight lakh.

“I am extremely happy and I congratulate the scientists involved in the cutting-edge level. I hope the cost-effective device will be available in the market in the next eight months to help ensure ..

The Minister said with this device it will be easy to screen and detect cervical cancer in its early stages, thus making treatment more effective.

“We will also ensure proper training of nurses and manpower for using the device in the coming months,” he said, adding that screening for cervical cancer is available only in regional cancer institutes and medical colleges at present.

He said the equipment presently being used is expensive, as a result of which not many medical coll ..

Source: Economic Times